From October 1, 2023 to December 31, 2023, the company has repurchased 1,349,500 shares, representing 2.95% for ¥4,246.78 million. With this, the company has completed the repurchase of 1,664,100 shares, representing 3.63% for ¥5,196.6 million under the buyback announced on May 8, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,165 JPY | -0.31% |
|
+0.64% | +2.43% |
06-10 | Kissei Pharmaceutical Licenses Linzagolix to JW Pharmaceutical for Korean Market | MT |
06-10 | Kissei Pharmaceutical Co., Ltd. Enters into License Agreement with Jw Pharmaceutical Corporation | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.43% | 880M | |
+14.71% | 77.46B | |
+13.86% | 8.94B | |
-24.30% | 4.28B | |
+12.79% | 4.18B | |
+31.45% | 4.11B | |
+9.54% | 2.23B | |
-30.57% | 2.06B | |
+8.99% | 1.97B | |
-45.76% | 1.69B |
- Stock Market
- Equities
- 4547 Stock
- News Kissei Pharmaceutical Co., Ltd.
- Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.